CSPC Pharmaceutical Group Limited (CVG) - Total Liabilities
Based on the latest financial reports, CSPC Pharmaceutical Group Limited (CVG) has total liabilities worth €11.14 Billion EUR (≈ $13.02 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CSPC Pharmaceutical Group Limited - Total Liabilities Trend (2013–2024)
This chart illustrates how CSPC Pharmaceutical Group Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CSPC Pharmaceutical Group Limited Competitors by Total Liabilities
The table below lists competitors of CSPC Pharmaceutical Group Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Encompass Health Corp
NYSE:EHC
|
USA | $3.81 Billion |
|
Dynatrace Holdings LLC
NYSE:DT
|
USA | $1.35 Billion |
|
CCL Industries Inc
TO:CCL-B
|
Canada | CA$4.92 Billion |
|
Zhejiang Chint Electrics Co
SHG:601877
|
China | CN¥102.54 Billion |
|
Deutsche Lufthansa AG
XETRA:LHA
|
Germany | €37.41 Billion |
|
Renault SA
F:RNL1
|
Germany | €96.29 Billion |
|
Maplebear Inc.
NASDAQ:CART
|
USA | $1.17 Billion |
|
Western Mining Co Ltd
SHG:601168
|
China | CN¥34.01 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down CSPC Pharmaceutical Group Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CSPC Pharmaceutical Group Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CSPC Pharmaceutical Group Limited (2013–2024)
The table below shows the annual total liabilities of CSPC Pharmaceutical Group Limited from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €10.52 Billion ≈ $12.30 Billion |
-6.58% |
| 2023-12-31 | €11.26 Billion ≈ $13.17 Billion |
+11.22% |
| 2022-12-31 | €10.13 Billion ≈ $11.84 Billion |
+27.99% |
| 2021-12-31 | €7.91 Billion ≈ $9.25 Billion |
+13.55% |
| 2020-12-31 | €6.97 Billion ≈ $8.15 Billion |
+2.48% |
| 2019-12-31 | €6.80 Billion ≈ $7.95 Billion |
-11.36% |
| 2018-12-31 | €7.67 Billion ≈ $8.97 Billion |
+49.65% |
| 2017-12-31 | €5.13 Billion ≈ $5.99 Billion |
+25.32% |
| 2016-12-31 | €4.09 Billion ≈ $4.78 Billion |
-13.46% |
| 2015-12-31 | €4.73 Billion ≈ $5.53 Billion |
+8.68% |
| 2014-12-31 | €4.35 Billion ≈ $5.09 Billion |
-5.52% |
| 2013-12-31 | €4.60 Billion ≈ $5.38 Billion |
-- |
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more